Search Results
Your search for early matches 10467 pages
Showing 7301 - 7350ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
Eribulin in Liposarcoma: A Closer Look at the Comparative Data
Sarcoma therapy is a challenge for oncologists. Soft-tissue sarcomas encompass more than 50 different histologies, resulting in limited familiarity of management for many treating physicians. In addition, there have been few available effective therapies. The phase III trial of eribulin (Halavan) ...
Increased Physical Activity Associated With Lower Risk of 13 Types of Cancer
A new study of the relationship between physical activity and cancer has shown that greater levels of leisure-time physical activity were associated with a lower risk of developing 13 different types of cancer. The risk of developing seven cancer types was 20%, or more, lower among the...
Atezolizumab in Previously Treated Advanced Urothelial Carcinoma
The recent study by Rosenberg et al in The Lancet—summarized in this issue of The ASCO Post—is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the...
Anti–PD-L1 Antibody Atezolizumab Active in Previously Treated Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and colleagues found that the anti–PD-L1 (programmed cell death ligand 1) antibody atezolizumab produced durable responses in a marked proportion of patients with previously treated...
Curb Your Enthusiasm: No Benefit of Adjuvant Sorafenib or Sunitinib in Nonmetastatic Renal Cell Carcinoma
Renal cell carcinoma is the most common cancer of the kidneys. Up to 30% of patients present with advanced/metastatic disease, and recurrence can develop in patients at high risk treated by nephrectomy for localized tumors. Renal cell carcinoma is notoriously resistant to chemotherapy and...
No Disease-Free Survival Benefit of Adjuvant Sunitinib or Sorafenib in High-Risk Nonmetastatic Renal Cell Carcinoma
In the phase III ECOG-ACRIN E2805 trial reported in The Lancet by Naomi B. Haas, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, no benefit of adjuvant vascular endothelial growth factor receptor (VEGFR) inhibitor treatment with sunitinib or sorafenib (Nexavar) was...
ASCO and European Association of Urology Agree on Bladder Cancer Guidelines
I like economies of scale, and thus it makes perfect sense that ASCO has set a formal process to allow potential endorsement of selected guidelines from other organizations, rather than redoing the whole process. Recently, we have seen the publication of a formal endorsement of the European...
ASCO Endorses European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancers
As reported in the Journal of Clinical Oncology by Matthew I. Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and colleagues,1 ASCO has endorsed the European Association of Urology clinical practice guideline on muscle-invasive and metastatic bladder...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
On Monday, April 11, ASCO released a policy statement calling on member oncologists to help lead a push for all adolescents and young adults to be vaccinated against cervical and other cancer. Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported by Pascal Hammel, MD, of Beaujon Hospital, Clichy, France, and colleagues in JAMA, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine...
ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
Neratinib Improves Invasive Disease–Free Survival in HER2-Positive Breast Cancer
In the phase III ExteNET trial reported in The Lancet Oncology, Arlene Chan, MD, of the Breast Cancer Research Centre-Western Australia, Perth, and colleagues found that 1 year of treatment with the HER1, HER2, and HER4 tyrosine kinase inhibitor neratinib improved invasive disease–free survival...
Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Patients With Stage IV Breast Cancer
In a study reported in the Journal of Clinical Oncology, Check et al identified disparities in supportive medication use and end-of-life care between black and white Medicare patients with stage IV breast cancer. Study Details The study involved SEER (Surveillance, Epidemiology, and End...
Lifang Hou, MD, PhD, Named Director of Global Health at the Lurie Cancer Center
Lifang Hou, MD, PhD, has been appointed Director of Global Health for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Hou brings her extensive experience in identifying risk factors and molecular biomarkers predictive of cancer risk and mortality, her interest in...
Survey Finds Most Americans Unlikely to Enroll in Clinical Trials
According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35% of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4% of cancer...
ODAC Advises the FDA to Wait for Phase III Results for Rociletinib in Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met April 12 to consider a New Drug Application by Clovis Oncology for rociletinib, an investigational therapy for epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) in patients...
Venetoclax for Previously Treated Chronic Lymphocytic Leukemia With 17p Deletion
On April 11, 2016, venetoclax (Venclexta) was approved for treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have received at least one prior therapy.1,2 The accelerated approval was based...
Gene Rearrangements: Attractive Targets in a Variety of Cancers
Entrectinib, a potent investigational tyrosine kinase inhibitor, exhibited promising clinical activity in a pooled analysis of two phase I trials of patients with solid metastatic tumors that harbored any of five specific genetic rearrangements involving NTRK1, NTRK2, NTRK3, ROS1, or ALK....
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
Crizotinib Active in Orphan Kidney Malignancy
Crizotinib (Xalkori) achieved overall and durable responses in advanced inoperable papillary renal cell carcinoma type 1 characterized by somatic MET mutations, according to an investigator-initiated trial conducted by the European Organization for Research and Treatment of Cancer (EORTC).1 “To...
Fitness: Can Exercise Lengthen Survival in Patients With Cancer?
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, of Memorial Sloan Kettering Cancer Center, New York. Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy...
Ushering in a New Era in Personalized Medicine
When Waun Ki Hong, MD, and his pregnant wife, Mihwa, made the journey from Korea to Manhattan in 1970, he had just $451 in his wallet, and the only job he could get was as an intern in Bronx-Lebanon Hospital Center, a community hospital in the Bronx. The work was grueling—24-hour shifts every 2...
CancerLinQ Completes Agreements With 36 ‘Vanguard’ Practices
CancerLinQ LLC announced on April 21 that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology platform that will harness big data analytics to help oncologists rapidly improve high-quality ...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2016 Guidelines
In 1996, the National Comprehensive Cancer Network (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), covering eight tumor types. The NCCN Guidelines® are now published for more than 60 tumor types and topics. Some of the key updates for 2016 were...
Recent Reports on Treatment for Leukemias, Sinusoidal Obstruction Syndrome, and Graft-vs-Host Disease
In this installment of Hematology Expert Review, I will summarize five studies from the recent literature addressing important questions about leukemias and their treatment, anticoagulant therapy with the new agent defibrotide (Defitelio), and the use of antilymphocyte globulin to prevent chronic...
FDA Approves Nivolumab for Heavily Pretreated Classical Hodgkin Lymphoma
On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the programmed cell death protein 1 (PD‑1) inhibitor, nivolumab (Opdivo), for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem...
How Immunotherapy Is Revolutionizing Cancer Care
More than 100 years after William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill them, the recognition of immunotherapy as a powerful anticancer therapy is finally being...
Pembrolizumab Survival Benefit Proves Durable in Patients With Advanced Melanoma
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
What ASCO Can Do for You—and for Our Patients
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival...
A Psychotherapist’s Approach to End-of-Life Care
BookmarkTitle: Dying: A TransitionAuthor: Monika Renz, PhD; translated by Mark Kyburz and John PeckPublisher: Columbia University PressPublication date: October 2015Price: $38.00; hardcover, 176 pages The night before Julius Caesar was assassinated, he had dinner with his friend Marcus...
In Celebration of a Remarkable Career at ASCO
In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...
Characterization of Molecular Differences in Cancer Between Male and Female Patients
It is well known that men and women differ in terms of cancer susceptibility, survival, and mortality, but exactly why this occurs at a molecular level has been poorly understood. A study at The University of Texas MD Anderson Cancer Center reviewed 13 cancer types and provided a molecular...
Use of Complementary and Alternative Medicine Affects Breast Cancer Chemotherapy Initiation
Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND,...
ASCO 2016: Autologous Stem Cell Transplant Remains Relevant in Multiple Myeloma, Even in Era of Novel Agents
Early findings from a phase III clinical trial (EMN02/HO95 MM) showed that patients with multiple myeloma who received an autologous stem cell transplant survived longer without disease progression than those who received only chemotherapy using novel agents. This is the largest study reported to...
ASCO 2016: Early Palliative Care Provides Benefits for Family Caregivers of Patients With Cancer
A randomized clinical trial found that introducing palliative care shortly after a cancer diagnosis results in better quality of life and fewer symptoms of depression among family caregivers. According to the authors, the study is the first to show that early palliative care alone for a...
ASCO 2016: PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma in KEYNOTE-001
Long-term follow-up from a phase Ib trial (KEYNOTE-001) in newly diagnosed and previously treated patients with advanced melanoma showed that 40% of patients were alive 3 years after starting the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda), with similar 36-month...
FDA Grants Accelerated Approval to Nivolumab in Classical Hodgkin Lymphoma
On May 17, 2016, the U.S. Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and...
No Survival Benefit Reported With Chemoradiotherapy vs Continued Chemotherapy in Controlled Locally Advanced Pancreatic Cancer
In the phase III GERCOR LAP07 trial reported in JAMA by Hammel et al, there was no survival benefit of chemoradiotherapy vs continued chemotherapy in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib (Tarceva). Study Details In...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al in CA: A ...
AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial
A promising new test is detecting prostate cancer more precisely than current tests by identifying molecular changes in the prostate-specific antigen (PSA) protein, according to Cleveland Clinic research presented at the 111th Annual Scientific Meeting of the American Urological Association (AUA)...
Factors Associated With Response to Dabrafenib/Trametinib in BRAF Inhibitor–Refractory Metastatic Melanoma
Poor response to combined BRAF and MEK inhibition with dabrafenib (Tafinlar)/trametinib (Mekinist) in patients with BRAF inhibitor–refractory metastatic melanoma may be associated with failure to significantly inhibit the MAPK pathway, according to a single-center phase II study reported in...
Study of SEER Data Identifies Racial/Ethnic Disparities in Survival in Patients With Young-Onset Colorectal Cancer
In a study of Surveillance, Epidemiology, and End Results (SEER) data reported in the Journal of Clinical Oncology, Holowatyj et al found that survival was significantly poorer in black vs white patients diagnosed with colorectal cancer between the ages of 20 and 49 years. Study Details The...
AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
FDA Launches First Campaign Focused on Dangers of Smokeless Tobacco Among Rural Teens
The U.S. Food and Drug Administration (FDA) has announced it is expanding its award-winning “The Real Cost” campaign to educate rural white male teenagers about the negative health consequences associated with smokeless tobacco use. For the first time, messages on the dangers of smokeless tobacco...
Breakthrough Therapy Efforts Result in Unprecedented Success
Friends of Cancer Research (Friends) and the U.S. Food and Drug Administration (FDA) have been working together for many years on an idea known as breakthrough therapy, and it has produced results beyond anyone’s hopes. Said Ellen Sigal, PhD, Friends Chair and Founder, “When we were first talking...
Clinical Trials Actively Recruiting Patients With Ewing Sarcoma
Phase I Study Title: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy-Refractory Ewing Sarcoma Study Type: Interventional/nonrandomized/single-group assignment Study Sponsor and Collaborators: University of Louisville Purpose: To examine the...
